Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL1B | P01584 | 6/20 | 0.48 |
| ▸ | NLRP3 | Q96P20 | 4/20 | 0.48 |
| ▸ | CNR2 | P34972 | 9/20 | 0.47 |
| ▸ | TNF | P01375 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | PPARG | P37231 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | NR2E3 | Q9Y5X4 | 1/20 | 0.34 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31199719 | 0.84 | CNR2 (0.67) | IL1BNLRP3CNR2TNFKMT2A | |
| SCHEMBL31199385 | 0.82 | CNR2 (0.56) | IL1BNLRP3CNR2TNFL3MBTL1 | |
| SCHEMBL31199549 | 0.82 | CNR2 (0.56) | IL1BNLRP3CNR2TNFL3MBTL1 | |
| SCHEMBL31199454 | 0.82 | IL1B (0.46) | IL1BNLRP3CNR2TNFL3MBTL1 | |
| SCHEMBL31199508 | 0.79 | CNR2 (0.48) | IL1BNLRP3CNR2TNFL3MBTL1 | |
| SCHEMBL31199540 | 0.79 | IL1B (0.49) | IL1BNLRP3CNR2TNF | |
| SCHEMBL31199649 | 0.79 | IL1B (0.47) | IL1BNLRP3CNR2TNFNPC1 | |
| SCHEMBL31199406 | 0.78 | IL1B (0.46) | IL1BNLRP3CNR2TNFL3MBTL1 | |
| SCHEMBL31199632 | 0.77 | IL1B (0.46) | IL1BNLRP3CNR2TNFL3MBTL1 | |
| SCHEMBL31199359 | 0.76 | IL1B (0.48) | IL1BNLRP3CNR2TNF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4680601-A1 | PYRIDAZINE COMPOUNDS, THEIR PREPARATION, AND THEIR THERAPEUTIC USES | Sanofi (FR) | 2026-01-21 | — | — | EP | claimed |
| US-20240360151-A1 | PYRIDAZINE COMPOUNDS, THEIR PREPARATION, AND THEIR THERAPEUTIC USES | SANOFI (FR) | 2024-10-31 | — | — | US | claimed |
| WO-2024188994-A1 | PYRIDAZINE COMPOUNDS, THEIR PREPARATION, AND THEIR THERAPEUTIC USES | SANOFI (FR) | 2024-09-19 | — | — | WO | claimed |
| EP-4680601-A1 | PYRIDAZINE COMPOUNDS, THEIR PREPARATION, AND THEIR THERAPEUTIC USES | Sanofi (FR) | 2026-01-21 | — | — | EP | disclosed |
| US-20240360151-A1 | PYRIDAZINE COMPOUNDS, THEIR PREPARATION, AND THEIR THERAPEUTIC USES | SANOFI (FR) | 2024-10-31 | — | — | US | disclosed |
| WO-2024188994-A1 | PYRIDAZINE COMPOUNDS, THEIR PREPARATION, AND THEIR THERAPEUTIC USES | SANOFI (FR) | 2024-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240360151-A1 | PYRIDAZINE COMPOUNDS, THEIR PREPARATION, AND THEIR THERAPEUTIC USES | NLRP3, NOD1, NLRP1 | IL1B 66/4885NLRP3 1/4885CNR2 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.